Abstract:The recent approval of a prostate cancer vaccine has renewed hope for anticancer immunotherapies. However, the immunosuppressive tumor microenvironment may limit the effectiveness of current immunotherapies. Antiangiogenic agents have the potential to modulate the tumor microenvironment and improve immunotherapy, but they often are used at high doses in the clinic to prune tumor vessels and paradoxically may compromise various therapies. Here, we demonstrate that targeting tumor vasculature with lower vascular-normalizing doses, but not high antivascular/antiangiogenic doses, of an anti-VEGF receptor 2 (VEGFR2) antibody results in a more homogeneous distribution of functional tumor vessels. Furthermore, lower doses are superior to the high doses in polarizing tumor-associated macrophages from an immune inhibitory M2-like phenotype toward an immune stimulatory M1-like phenotype and in facilitating CD4 + and CD8 + T-cell tumor infiltration. Based on this mechanism, scheduling lower-dose anti-VEGFR2 therapy with T-cell activation induced by a whole cancer cell vaccine therapy enhanced anticancer efficacy in a CD8 + T-cell–dependent manner in both immune-tolerant and immunogenic murine breast cancer models. These findings indicate that vascular-normalizing lower doses of anti-VEGFR2 antibody can reprogram the tumor microenvironment away from immunosuppression toward potentiation of cancer vaccine therapies. Given that the combinations of high doses of bevacizumab with chemotherapy have not improved overall survival of breast cancer patients, our study suggests a strategy to use antiangiogenic agents in breast cancer more effectively with active immunotherapy and potentially other anticancer therapies.

Anti-angiogenic Nano-Delivery System Promotes Tumor Vascular Normalizing and Micro-Environment Reprogramming in Solid Tumor

Modulating Tumour Vascular Normalisation Using Triptolide-Loaded NGR-functionalized Liposomes for Enhanced Cancer Radiotherapy

"Targeted Plus Controlled" - Composite Nano Delivery System Opens the Tumor Vascular and Microenvironment Normalization Window for Anti-Tumor Therapy.

Metabolic Symbiosis‐Blocking Nano‐Combination for Tumor Vascular Normalization Treatment

Reshaping Tumor Blood Vessels to Enhance Drug Penetration with a Multistrategy Synergistic Nanosystem

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy

Recent advances of nanotechnology-based tumor vessel-targeting strategies

Nitric oxide nano-reactor DNMF/PLGA enables tumor vascular microenvironment and chemo-hyperthermia synergetic therapy

Tumor vasculature and microenvironment normalization: a possible mechanism of antiangiogenesis therapy.

Anti-angiogenic Therapy for Tumor: Tumor Angiogenesis, Vasculogenic Mimicry and Vascular Normalization

Remodeling the tumor microenvironment by vascular normalization and GSH-depletion for augmenting tumor immunotherapy

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

Inducing Vascular Normalization: A Promising Strategy for Immunotherapy.

Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies

Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy

Normalizing Tumor Blood Vessels to Improve Chemotherapy and Inhibit Breast Cancer Metastasis by Multifunctional Nanoparticles.

Active molecule-based theranostic agents for tumor vasculature normalization and antitumor efficacy

Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization

Polymer-Modified Lipid Nanoparticles with Microenvironment-Responsive Graded Release for Amplified Photodynamic Therapy Through Tumor Vascular Normalization

Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy